Filter Results:
(1,363)
Show Results For
- All HBS Web
(6,131)
- Faculty Publications (1,363)
Show Results For
- All HBS Web
(6,131)
- Faculty Publications (1,363)
- October 2023
- Supplement
Hey Jane: Early Investor Pitch Deck
By: Rembrand Koning
Keywords: Health Care and Treatment; Operations; Entrepreneurial Finance; Health Industry; Health Industry; United States
Koning, Rembrand. "Hey Jane: Early Investor Pitch Deck." Harvard Business School Supplement 724-409, October 2023.
- October 2023
- Background Note
What Leaders Need to Know about Mental Health
By: Boris Groysberg, Robin Abrahams, Liana Groysberg, Natalia Groysberg and Abhijit Naik
This paper will provide an overview of the nature of anxiety and depression, the particular vulnerabilities and stresses of CEOs, and suggestions for managing mental health in the workplace. View Details
Groysberg, Boris, Robin Abrahams, Liana Groysberg, Natalia Groysberg, and Abhijit Naik. "What Leaders Need to Know about Mental Health." Harvard Business School Background Note 424-032, October 2023.
- 2023
- Working Paper
The Political Economy of a 'Miracle Cure': The Case of Nebulized Ibuprofen and Its Diffusion in Argentina
By: Sebastian Calónico, Rafael Di Tella and Juan Cruz Lopez Del Valle
We document the diffusion of nebulized ibuprofen in Argentina as a treatment for COVID-19. As the pandemic spread, this clinically unsupported drug reached thousands of patients, even some seriously ill, despite warnings by the regulator and medical societies. Detailed... View Details
Keywords: COVID-19; Health Care and Treatment; Health Pandemics; Adoption; Behavior; Governing Rules, Regulations, and Reforms; Learning
Calónico, Sebastian, Rafael Di Tella, and Juan Cruz Lopez Del Valle. "The Political Economy of a 'Miracle Cure': The Case of Nebulized Ibuprofen and Its Diffusion in Argentina." NBER Working Paper Series, No. 31781, October 2023.
- October 2023
- Case
Vida Health: Transforming Chronic Disease Treatment
By: William Sahlman and Nicole Tempest Keller
San Francisco based Vida Health, founded by Stephanie Tilenius, former vice president of Commerce and Payments at Google, was a B2B digital health startup focused on the treatment of cardiometabolic conditions, such as diabetes and obesity. Its innovative digital... View Details
Keywords: Corporate Strategy; Growth and Development Strategy; Demand and Consumers; Health Care and Treatment; Product Marketing; Risk and Uncertainty; Technological Innovation; Health Industry; Health Industry; United States; California; San Francisco
Sahlman, William, and Nicole Tempest Keller. "Vida Health: Transforming Chronic Disease Treatment." Harvard Business School Case 824-001, October 2023.
- 2023
- Working Paper
Are Hospital Quality Indicators Causal?
By: Amitabh Chandra, Maurice Dalton and Douglas O. Staiger
Hospitals play a key role in patient outcomes and spending, but efforts to improve their quality are hindered because we do not know whether hospital quality indicators are causal or biased. We evaluate the validity of commonly used quality indicators, such as... View Details
Keywords: Quality; Health Care and Treatment; Measurement and Metrics; Outcome or Result; Health Industry
Chandra, Amitabh, Maurice Dalton, and Douglas O. Staiger. "Are Hospital Quality Indicators Causal?" NBER Working Paper Series, No. 31789, October 2023.
- October 2023
- Article
Health System Perspective on Cost for Delivering a Decision Aid for Prostate Cancer Using Time-Driven Activity-Based Costing
By: David R. Ho, Robert S. Kaplan, Jonathan Bergman, David F. Penson, Benjamin Waterman, Kristin C. Williams, Jefersson Villatoro, Lorna Kwan and Christopher S. Saigal
Previsit decision aids (DAs) have been shown to improve decisional quality. But the cost to deploy a DA has not been previously estimated. We interviewed or observed relevant personnel at three institutions that had implemented DA programs for men with prostate cancer.... View Details
Keywords: Time-Driven Activity-Based Costing; Health Care and Treatment; Cost Accounting; Health Industry
Ho, David R., Robert S. Kaplan, Jonathan Bergman, David F. Penson, Benjamin Waterman, Kristin C. Williams, Jefersson Villatoro, Lorna Kwan, and Christopher S. Saigal. "Health System Perspective on Cost for Delivering a Decision Aid for Prostate Cancer Using Time-Driven Activity-Based Costing." Medical Care 61, no. 10 (October 2023): 681–688.
- September 2023 (Revised January 2024)
- Case
AB InBev: Brewing Up Forecasts during COVID-19
By: Mark Egan, C. Fritz Foley, Esel Cekin and Emilie Billaud
In July 2021, the CEO of AB InBev's European operations and his team strategized to position the company for success post-pandemic. As the world's largest beer company, boasting over 500 brands, revenue of $46 billion, and a workforce of 160,000 in 2020, AB InBev... View Details
Keywords: Beer; Forecasting; COVID-19; Decision; Forecasting and Prediction; Analytics and Data Science; Crisis Management; Decisions; Financing and Loans; Investment Return; Resource Allocation; Distribution; Production; Business Processes; Strategic Planning; Health Pandemics; Digital Transformation; Markets; Food and Beverage Industry; Belgium; Europe; Latin America; North and Central America
Egan, Mark, C. Fritz Foley, Esel Cekin, and Emilie Billaud. "AB InBev: Brewing Up Forecasts during COVID-19." Harvard Business School Case 224-020, September 2023. (Revised January 2024.)
- September 2023
- Teaching Note
Roche: ESG and Access to Healthcare
By: George Serafeim
Teaching Note for HBS Case No. 123-075. In May 2022, Roche Group, one of the largest healthcare companies in the world, hosted its first ESG investor event focused exclusively on its efforts to impact access to healthcare. While Roche had recently set an ambitious goal... View Details
- September 2023
- Supplement
Fighting the Battle of the Bulge—Evaluating Do Good/Do Well Innovations in Morbid Obesity Treatment
This PowerPoint accompanies Regina E. Herzlinger's "Fighting the Battle of the Bulge – Evaluating Do Good/Do Well Innovations in Morbid Obesity Treatment" teaching note (HBS Case No.324-013) and is designed for instructors to use in the classroom when teaching this... View Details
- September 2023
- Teaching Note
Fighting the Battle of the Bulge—Evaluating Do Good/Do Well Innovations in Morbid Obesity Treatment
Teaching Note for HBS Case No. 304-009. The case is part of the first module of the Innovating in Health Care course. Its purpose is to demonstrate how to evaluate the “do good” and do well” potential of a health care innovation. View Details
- September–October 2023
- Article
Prospective Evaluation of the Cost of Performing Breast Imaging Examinations Using Time-Driven Activity-Based Costing Method: A Single Center Study
By: Aamir Ali, Jordana Phillips, Damir Ljuboja, Syed S. Shehab, Etta D. Pisano, Robert S. Kaplan and Ammar Sarwar
We use time-driven activity-based costing (TDABC) to measure the cost of performing breast imaging using different modalities: full-field digital mammography (FFDM), digital breast tomosynthesis (DBT), contrast-enhanced mammography (CEM), US and MRI exams, and... View Details
Keywords: Time-Driven Activity-Based Costing; Health Care; Breast Cancer; Health Care and Treatment; Cost; Cost Accounting; Health Industry
Ali, Aamir, Jordana Phillips, Damir Ljuboja, Syed S. Shehab, Etta D. Pisano, Robert S. Kaplan, and Ammar Sarwar. "Prospective Evaluation of the Cost of Performing Breast Imaging Examinations Using Time-Driven Activity-Based Costing Method: A Single Center Study." Journal of Breast Imaging 5, no. 5 (September–October 2023): 546–554.
- October 2023
- Article
What Does the Inflation Reduction Act Mean for Patients and Physicians?
By: Amitabh Chandra and Benedic Ippolito
The debate around prescription drug measures in the recently passed U.S. Inflation Reduction Act (IRA), which limit some patients’ out-of-pocket costs, has not fully addressed their effect on physicians and patients via their effect on payers. Reducing patients’ costs... View Details
Chandra, Amitabh, and Benedic Ippolito. "What Does the Inflation Reduction Act Mean for Patients and Physicians?" NEJM Catalyst Innovations in Care Delivery 4, no. 10 (October 2023).
- August 2023
- Case
Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company
By: Satish Tadikonda and Brad Prosek
Constellation Pharmaceuticals was a company focused on epigenetic therapies for cancer patients. Despite a promising start and an early deal with a leading biopharma company, the company weathered twin setbacks in the end of a major research collaboration and the... View Details
Keywords: Mergers and Acquisitions; Health Care and Treatment; Organizational Change and Adaptation; Research and Development; Business Strategy; Partners and Partnerships; Goals and Objectives; Pharmaceutical Industry; United States
Tadikonda, Satish, and Brad Prosek. "Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company." Harvard Business School Case 824-032, August 2023.
- August 2023
- Teaching Note
Vanderbilt: Transforming an Academic Health Care Delivery System, 2020
By: Michael E. Porter, Robert S. Kaplan, Mary L. Witkowski and David N. Bernstein
Teaching Note for HBS Case No. 724-373. View Details
- August 2023
- Case
Vanderbilt: Transforming an Academic Health Care Delivery System, 2020
By: Michael E. Porter, Robert S. Kaplan, Mary L. Witkowski and David N. Bernstein
Keywords: Health Care; Health Care Industry; Academic Medicine; Value-based Health Care; Value-based Healthcare; Health Care Delivery; Service Delivery; Transformation; Health Care and Treatment; Corporate Strategy; Leadership; Health Industry; Tennessee; United States
Porter, Michael E., Robert S. Kaplan, Mary L. Witkowski, and David N. Bernstein. "Vanderbilt: Transforming an Academic Health Care Delivery System, 2020." Harvard Business School Case 724-373, August 2023.
- July–August 2023
- Article
Investing in Growth Through Uncertainty
By: Ranjay Gulati
When faced with disruptions and downturns, many leaders and companies instinctively focus on cutting costs to maintain profitability. But some identify opportunities and then take thoughtful action to emerge from crisis even stronger. That means not only planning for... View Details
Gulati, Ranjay. "Investing in Growth Through Uncertainty." Harvard Business Review 101, no. 4 (July–August 2023): 36–42.
- 2023
- Article
Evidence from the First Shared Medical Appointments (SMAs) Randomised Controlled Trial in India: SMAs Increase the Satisfaction, Knowledge, and Medication Compliance of Patients with Glaucoma
By: Nazlı Sönmez, Kavitha Srinivasan, Rengaraj Venkatesh, Ryan W. Buell and Kamalini Ramdas
In Shared Medical Appointments (SMAs), patients with similar conditions meet the physician together and each receives one-on-one attention. SMAs can improve outcomes and physician productivity. Yet privacy concerns have stymied adoption. In physician-deprived nations,... View Details
Sönmez, Nazlı, Kavitha Srinivasan, Rengaraj Venkatesh, Ryan W. Buell, and Kamalini Ramdas. "Evidence from the First Shared Medical Appointments (SMAs) Randomised Controlled Trial in India: SMAs Increase the Satisfaction, Knowledge, and Medication Compliance of Patients with Glaucoma." e0001648. PLoS Global Public Health 3, no. 7 (2023).
- Summer 2023
- Article
Do Policies to Increase Access to Treatment for Opioid Use Disorder Work?
By: Eric Barrette, Leemore S. Dafny and Karen Shen
Even among commercially insured individuals, opioid use disorder is undertreated in the United States: nearly half receive no treatment within six months of a new diagnosis. Using a difference-in-differences specification exploiting the extension of insurance parity... View Details
Keywords: Opioid Treatment; Medication-assisted Treatment; Substance Use Disorder; Private Insurance; Insurance; Health Care and Treatment
Barrette, Eric, Leemore S. Dafny, and Karen Shen. "Do Policies to Increase Access to Treatment for Opioid Use Disorder Work?" American Journal of Health Economics 9, no. 3 (Summer 2023): 297–330.
- June 2023
- Supplement
Roche: ESG and Access to Healthcare
By: George Serafeim
In May 2022, Roche Group, one of the largest healthcare companies in the world, hosted its first ESG investor event focused exclusively on its efforts to impact access to healthcare. While Roche had recently set an ambitious goal to double the number of patients that... View Details
Keywords: ESG (Environmental, Social, Governance) Performance; Sustainable Finance; Growth Strategy And Execution; Sustainability Targets; Impact Evaluation; Healthcare Access; Healthcare Innovation; Healthcare Systems; Healthcare Operations; Finance; Strategy; Health Testing and Trials; Health Care and Treatment; Growth Management; Measurement and Metrics; Innovation Strategy; Corporate Social Responsibility and Impact; Health Industry; Health Industry; Switzerland; North America; Europe; Asia; Latin America; Africa
Serafeim, George. "Roche: ESG and Access to Healthcare." Harvard Business School Multimedia/Video Supplement 123-713, June 2023.
- 3 Jun 2023
- Talk
Health Care Innovation Opportunities Created by COVID-19 and How to Make Them Happen
The crush of patients created by COVID enabled the creation of sites for care outside the traditional hospital, such as retail pharmacies, ambulatory surgery centers, urgent care centers, telemedicine, and wireless sensors. Public policy mirrored these changes by... View Details
Keywords: Policy; Health Pandemics; Health Care and Treatment; Innovation and Invention; Health Industry; Health Industry
Herzlinger, Regina E. "Health Care Innovation Opportunities Created by COVID-19 and How to Make Them Happen." Harvard Business School Alumni Reunion, Boston, MA, June 3, 2023. (Link to cases described in this talk.)